Tagged with EG

Belgium Janssen has the lofty aim of reaching USD 60bn dollars in sales by 2025, an 8bn increase on the 2021 figure, despite some high-profile losses of exclusivity and the spin-off of its consumer healthcare branch. This massive growth plan involves both existing products as well as new CAR-T and autoimmune…

Hong Kong Bio-Gene, part of the Pangenia Group, is one of Hong Kong’s most notable life science success stories, with operations in the laboratory supply of instruments, reagents and consumables. Desmond Hau, PhD, who founded the company back in 1993, outlines its growth trajectory, how the Hong Kong innovation ecosystem is evolving,…

Americas Writing in the August edition of DIA’s Global Forum magazine, Silvia B. Bendiner of WESSX Inc. and Belkis Romeu call for greater regulatory collaboration between Latin American countries, building on an initiative created by Dr. Rafael Pérez Cristiá at the Cuban Regulatory Authority (CECMED).   The need for further regulatory…

China Writing in the August edition of DIA’s Global Forum magazine, Wen Yin of the Pfizer China R&D Center and Wanhe Deng of GSK China Investment look back on four years of China’s marketing authorization holder (MAH)-based regulatory system, including the opportunities it presents, and some of the implementation challenges.  …

Belgium There have been both ups and downs in AbbVie’s recent history. After proving its staying power with the celebration of its 10-year anniversary as an independent company spun off from Abbott, the American drugmaker faced a less happy turning point as its leading drug Humira came up against stiff competition…

Europe Rainer Westermann, chairman of the Life Sciences Acceleration Alliance e.V. (LSAA), which lobbies on behalf of European venture capitalists in the life sciences space, critiques the draft EU Pharma Regulation from a VC perspective, arguing that the continent’s status as a medical innovation hub is at risk if the EU…

UAE Founded in July 2020, the Emirates Health Economics Society – led by Dr Sara Al Dallal – aims to create a space for the discussion of health economics within the UAE. In conversation with PharmaBoardroom, Dr Al Dallal outlines how the organisation’s collaborations with governmental, industry, and academic stakeholders are…

UAE Mohamed Ezz Eldin oversees Novartis operations in the UAE, Kuwait, Bahrain, Oman and Qatar. He outlines how the company’s strategy has evolved in the Gulf region following the spin-off of generics arm Sandoz and its now 100 percent focus on innovative medicines. Ezz Eldin also describes some of the key…

Hong Kong MSD’s managing director for Hong Kong and Macau, Vincent Tong, came to lead the affiliate during the COVID-19 pandemic. He outlines the challenges and opportunities of a challenging time, discusses the leading position of the company’s cancer treatment Keytruda and his efforts as board member of the Hong Kong Association…

Middle East & Africa Head of the Middle East region and GM for the Middle East & Africa affiliate, Basel Thaher outlines his 18-year career at Menarini and discusses the Italian family-run company’s footprint in the region where it has a direct presence in the UAE, Saudi Arabia, Tunisia, and Egypt and plans to…

Global  Speaking as GM and head of the Middle East, Turkey, and Africa region, Andrew Bird, who has since become Acino’s Interim Chief Executive Officer, discusses the Swiss company’s “being global but acting local” approach to emerging markets and outlines the importance of the META region, which accounts for 35 percent…

Belgium 20-year Astellas veteran Mark Dekker – now back in his home country of the Netherlands and overseeing the Benelux cluster having primarily developed his career in emerging European markets – outlines the strategic significance of the cluster to the company. Benelux is both a source and recipient of cutting-edge biopharmaceutical…